Universidad Peruana Cayetano Heredia

A research agenda for helminth diseases of humans: Intervention for control and elimination

Mostrar el registro sencillo del ítem

dc.contributor.author Prichard, R.K.
dc.contributor.author Basáñez, M.-G.
dc.contributor.author Boatin, B.A.
dc.contributor.author McCarthy, J.S.
dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Yang, G.-J.
dc.contributor.author Sripa, B.
dc.contributor.author Lustigman, S.
dc.date.accessioned 2022-01-18T19:34:38Z
dc.date.available 2022-01-18T19:34:38Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/11074
dc.description.abstract Recognising the burden helminth infections impose on human populations, and particularly the poor, major intervention programmes have been launched to control onchocerciasis, lymphatic filariasis, soil-transmitted helminthiases, schistosomiasis, and cysticercosis. The Disease Reference Group on Helminth Infections (DRG4), established in 2009 by the Special Programme for Research and Training in Tropical Diseases (TDR), was given the mandate to review helminthiases research and identify research priorities and gaps. A summary of current helminth control initiatives is presented and available tools are described. Most of these programmes are highly dependent on mass drug administration (MDA) of anthelmintic drugs (donated or available at low cost) and require annual or biannual treatment of large numbers of at-risk populations, over prolonged periods of time. The continuation of prolonged MDA with a limited number of anthelmintics greatly increases the probability that drug resistance will develop, which would raise serious problems for continuation of control and the achievement of elimination. Most initiatives have focussed on a single type of helminth infection, but recognition of co-endemicity and polyparasitism is leading to more integration of control. An understanding of the implications of control integration for implementation, treatment coverage, combination of pharmaceuticals, and monitoring is needed. To achieve the goals of morbidity reduction or elimination of infection, novel tools need to be developed, including more efficacious drugs, vaccines, and/or antivectorial agents, new diagnostics for infection and assessment of drug efficacy, and markers for possible anthelmintic resistance. In addition, there is a need for the development of new formulations of some existing anthelmintics (e.g., paediatric formulations). To achieve ultimate elimination of helminth parasites, treatments for the above mentioned helminthiases, and for taeniasis and food-borne trematodiases, will need to be integrated with monitoring, education, sanitation, access to health services, and where appropriate, vector control or reduction of the parasite reservoir in alternative hosts. Based on an analysis of current knowledge gaps and identification of priorities, a research and development agenda for intervention tools considered necessary for control and elimination of human helminthiases is presented, and the challenges to be confronted are discussed. en_US
dc.language.iso eng
dc.publisher Public Library of Science
dc.relation.ispartofseries PLoS Neglected Tropical Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Animals en_US
dc.subject Communicable Disease Control en_US
dc.subject endemic disease en_US
dc.subject parasite transmission en_US
dc.subject unclassified drug en_US
dc.subject vector control en_US
dc.subject morbidity en_US
dc.subject artemisinin en_US
dc.subject Drug Resistance en_US
dc.subject health program en_US
dc.subject review en_US
dc.subject methodology en_US
dc.subject drug effect en_US
dc.subject infection control en_US
dc.subject albendazole en_US
dc.subject fascioliasis en_US
dc.subject doxycycline en_US
dc.subject taeniasis en_US
dc.subject niclosamide en_US
dc.subject Anthelmintics en_US
dc.subject cysticercosis en_US
dc.subject nitazoxanide en_US
dc.subject oxfendazole en_US
dc.subject praziquantel en_US
dc.subject ivermectin en_US
dc.subject helminth en_US
dc.subject Helminthiasis en_US
dc.subject drug monitoring en_US
dc.subject medical education en_US
dc.subject triclabendazole en_US
dc.subject drug development en_US
dc.subject Drug Discovery en_US
dc.subject benzimidazole en_US
dc.subject mebendazole en_US
dc.subject soil en_US
dc.subject anthelmintic agent en_US
dc.subject parasite control en_US
dc.subject community en_US
dc.subject Helminths en_US
dc.subject Drug Therapy en_US
dc.subject schistosomiasis en_US
dc.subject lymphatic filariasis en_US
dc.subject diethylcarbamazine en_US
dc.subject onchocerciasis en_US
dc.subject clonorchiasis en_US
dc.subject derquantel en_US
dc.subject Education, Medical en_US
dc.subject emodepside en_US
dc.subject filariasis en_US
dc.subject levamisole en_US
dc.subject monepantel en_US
dc.subject moxidectin en_US
dc.subject opisthorchiasis en_US
dc.subject parasitism en_US
dc.subject pyrantel en_US
dc.subject tribendimidine en_US
dc.title A research agenda for helminth diseases of humans: Intervention for control and elimination en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1371/journal.pntd.0001549
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06
dc.relation.issn 1935-2735


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas